OPKO Health (NASDAQ:OPK) Releases Quarterly Earnings Results

OPKO Health (NASDAQ:OPK - Get Free Report) issued its quarterly earnings results on Thursday. The biotechnology company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.09, Zacks reports. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The firm had revenue of $183.60 million during the quarter, compared to the consensus estimate of $155.42 million.

OPKO Health Stock Up 0.6 %

Shares of OPK traded up $0.01 during trading hours on Monday, hitting $1.75. The stock had a trading volume of 29,653,360 shares, compared to its average volume of 4,457,309. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. The firm has a 50 day simple moving average of $1.55 and a 200-day simple moving average of $1.55. The firm has a market capitalization of $1.19 billion, a P/E ratio of -9.21 and a beta of 1.63. OPKO Health has a 1-year low of $0.86 and a 1-year high of $1.84.

Insider Activity

In related news, CEO Phillip Md Et Al Frost purchased 500,000 shares of the business's stock in a transaction on Wednesday, December 11th. The stock was acquired at an average price of $1.56 per share, for a total transaction of $780,000.00. Following the purchase, the chief executive officer now owns 212,411,477 shares of the company's stock, valued at approximately $331,361,904.12. This trade represents a 0.24 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders bought a total of 1,389,971 shares of company stock worth $2,124,442 in the last three months. Company insiders own 47.26% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. HC Wainwright reiterated a "buy" rating and set a $3.00 price target on shares of OPKO Health in a report on Monday. Barrington Research reiterated an "outperform" rating and set a $2.25 price target on shares of OPKO Health in a report on Friday. Finally, StockNews.com upgraded OPKO Health from a "sell" rating to a "hold" rating in a research note on Monday.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.